Related Experiment Videos
Embryotoxicity and teratogenicity of the anthracycline antibiotic carminomycin in mice
Research Communications in Chemical Pathology and Pharmacology
|June 1, 1980
Abstract:
Carminomycin, a new antitumor anthracycline antibiotic, has embryolethal, embryotoxic and teratogenic effects during early postimplantation stages of development in mice. These effects depend on the dose and route of administration and the gestational age of the exposed embryos.
Insights
Carminomycin, an antitumor antibiotic, causes birth defects in early mouse development. These embryotoxic and teratogenic effects are influenced by dosage, administration route, and embryo gestational age.
Area of Science:
- Pharmacology
- Developmental Toxicology
- Teratology
Background:
- Carminomycin is a novel anthracycline antibiotic with demonstrated antitumor properties.
- Anthracyclines are known for their potential toxicity, necessitating thorough safety evaluations.
Purpose of the Study:
- To investigate the developmental toxicity of carminomycin in mice.
- To characterize the embryolethal, embryotoxic, and teratogenic potential of carminomycin during early postimplantation development.
Main Methods:
- Administration of carminomycin to pregnant mice at various doses and via different routes.
- Evaluation of embryonic and fetal development at critical postimplantation stages.
- Assessment of dose-response and route-dependency of observed effects.
Main Results:
- Carminomycin exposure resulted in significant embryolethal, embryotoxic, and teratogenic effects.
- The severity of these effects was dependent on the dose administered.
- Route of administration and gestational age at exposure modulated the teratogenic outcomes.
Conclusions:
- Carminomycin exhibits significant developmental toxicity in mice during early postimplantation stages.
- Careful consideration of dosage, administration route, and timing of exposure is crucial to mitigate risks associated with carminomycin during pregnancy.